A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancerDaisuke Sakai, Toshihiko Doi, Shigenori Kadowaki et al.|Cancer Chemotherapy and Pharmacology|2017Cited by 31
Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysisSeiichiro Mitani, Kei Muro, Shigenori Kadowaki et al.|Cancer Medicine|2019Cited by 23